Pasithea Therapeutics Corp.
KTTAW·NasdaqCM
0.0028+0.0028 (0.00%)today
At close: Sep 15, 1:22 PM EST · May be delayed up to 15 min · USD
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Previous close0.0000
Open0.0122
Day range0.00270.0028
52-week range0.00270.0028
Off day high0.00%
Off 52-week high0.00%
Volume383
Avg. volume (3M)—
Market cap—
EPS (TTM)—
Forward P/E—
P/E ratio (TTM)—
Dividend yield—
Beta (5Y)0.29
Shares outstanding—
Short interest—
Earnings date—
Analyst target—
Profit margin0.00%
Against its peers
Compare in full ›| KTTAW | AB.PA | SUVEN.BO | PTCT | NBIX | FTH | |
|---|---|---|---|---|---|---|
| Market cap | — | 51.64M | 63.96B | 5.76B | 16.81B | 516.62M |
| P/E (TTM) | — | — | — | — | 24.6 | — |
| Forward P/E | — | -3.8 | 23.5 | 28.4 | 13.9 | -5.4 |
| Price/book | 0.0 | -1.8 | 21.8 | -30.1 | 4.3 | 1.4 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | — | −53.77% | +30.58% | −4.99% | +7.27% | +114.03% |
| Today | 0.00% | +1.33% | −0.14% | +1.25% | +0.73% | +1.73% |
The closest companies by business. Prices may be delayed up to 15 min.
Latest news
All KTTAW news ›Pasithea Therapeutics Highlights PAS-004’s Potential in NF1 at KOL Event
Posted by Michael Walen on Nov 4th, 2026 Pasithea Therapeutics (NASDAQ:KTTA) outlined the rationale, early clinical profile and market opportunity for its lead MEK inhibitor candidate, PAS-004, during a virtual key opinion leader event…
From the 4Search news index, newest first.
In the news
1mentions in 30 days
1with it in the headline
Positivesentiment
Mentioned with
People in the coverage
Most coverage from
- themarketsdaily.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 1 articles, not a forecast.